GI-ARS is a significant radiation toxicity that can result in sepsis and lead to death. Credit: Jo Panuwat D/Shutterstock. Synedgen has announced a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to develop its lead therapeutic, MIIST305, targeting […]
Synedgen partners with BARDA for MIIST305 development Read More »
Bladder cancer is the second most common urologic cancer in US men. Credit: SaiArLawKa2/Shutterstock. UroGen Pharma has received the new drug application (NDA) acceptance from the US Food and Drug Administration (FDA) for UGN-102 (mitomycin) for intravesical [directly into the
FDA accepts UroGen’s UGN-102 NDA for bladder cancer treatment Read More »
Efinaconazole’s low binding affinity to keratin enables it to penetrate nails effectively to treat onychomycosis. Credit: Prabodha D Herath/Shutterstock. Almirall has completed the decentralised European regulatory procedure for efinaconazole, a triazole antifungal substance with the trade name Jublia, to treat
Almirall completes EU regulatory procedure for Jublia Read More »
Boehringer Ingelheim partners with the WHO Foundation to financially support WHO’s Fourteenth General Programme of Work (2025 to 2028). Credit: PeopleImages.com – Yuri A/Shutterstock. Boehringer Ingelheim, in partnership with the WHO Foundation [an organisation set up to support the World
Boehringer partners with WHO Foundation Read More »
Lundbeck’s acquisition of Longboard Pharmaceuticals aims to bolster its neuro-rare conditions portfolio with the addition of bexicaserin. Credit: UnderhilStudio/Shutterstock. Lundbeck has signed an agreement to acquire Longboard Pharmaceuticals for $2.6bn equity value in a move set to enhance its capabilities
Lundbeck to acquire Longboard Pharmaceuticals for $2.6bn Read More »
ENHERTU is indicated for patients with unresectable or metastatic NSCLC with activating HER2 mutations who have previously undergone systemic therapy. Credit: Nemes Laszlo/Shutterstock. Daiichi Sankyo and AstraZeneca‘s ENHERTU has been conditionally approved by China’s National Medical Products Administration (NMPA) as
ENHERTU gains conditional approval in China Read More »
The decision marks a significant step in Sanofi’s ongoing effort to sharpen its focus on its core areas of innovative medicines and vaccines. Credit: jd8/Shutterstock. Sanofi has announced negotiations with Clayton Dubilier & Rice (CD&R), a US-based investment company, regarding
Sanofi in talks to sell stake in consumer healthcare unit to CD&R Read More »
The FDA approval of HYMPAVZI was supported by the Phase III BASIS clinical trial. Credit: Andrey_Popov/Shutterstock. Pfizer has announced the approval of HYMPAVZI (marstacimab-hncq) by the US Food and Drug Administration (FDA) for routine prophylaxis in patients with haemophilia A
FDA approves Pfizer’s HYMPAVZI to treat haemophilia Read More »
